These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21116617)

  • 1. New developments in the characterization of heparin and its impurities.
    Larive CK
    Anal Bioanal Chem; 2011 Jan; 399(2):525-6. PubMed ID: 21116617
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis and characterization of heparin impurities.
    Beni S; Limtiaco JF; Larive CK
    Anal Bioanal Chem; 2011 Jan; 399(2):527-39. PubMed ID: 20814668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the USP heparin monograph and implications for clinicians.
    Smythe MA; Nutescu EA; Wittkowsky AK
    Pharmacotherapy; 2010 May; 30(5):428-31. PubMed ID: 20411994
    [No Abstract]   [Full Text] [Related]  

  • 4. New developments in quantitative polymerase chain reaction applied to control the quality of heparins.
    Auguste C; Dereux S; Martinez C; Anger P
    Anal Bioanal Chem; 2011 Jan; 399(2):747-55. PubMed ID: 20931175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethylenediaminetetraacetic acid (EDTA) in heparin.
    Coyne E; Messmore HL; Walenga JM; Fareed J; Wehrmacher WH
    Thromb Res; 1998 Jun; 90(5):245-6. PubMed ID: 9694247
    [No Abstract]   [Full Text] [Related]  

  • 6. The troubled heparin issue in the Brazilian market and the search for solutions.
    Gomes WJ; Braile DM
    Rev Bras Cir Cardiovasc; 2009; 24(2):3-4. PubMed ID: 19768285
    [No Abstract]   [Full Text] [Related]  

  • 7. Development and validation of an ion-exchange chromatography method for heparin and its impurities in heparin products.
    Thiangthum S; Vander Heyden Y; Buchberger W; Viaene J; Prutthiwanasan B; Suntornsuk L
    J Sep Sci; 2014 Nov; 37(22):3195-204. PubMed ID: 25146711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anaphylactoid reactions associated with contaminated heparin from China].
    Montpas N; Désormeaux A; Keire D; Adam A
    Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of currently marketed heparin products: key tests for quality assurance.
    Keire DA; Ye H; Trehy ML; Ye W; Kolinski RE; Westenberger BJ; Buhse LF; Nasr M; Al-Hakim A
    Anal Bioanal Chem; 2011 Jan; 399(2):581-91. PubMed ID: 20680615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From crisis to opportunity: a perspective on the heparin crisis.
    Sasisekharan R; Shriver Z
    Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
    [No Abstract]   [Full Text] [Related]  

  • 11. The development of an FIA-CD strategy for screening sulfated polysaccharides using antimalarial drugs and related species as probes.
    Stanley FE; Warner AM; Stalcup AM
    Anal Bioanal Chem; 2011 Jan; 399(2):707-16. PubMed ID: 20941481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin pharmacovigilance in Brazil.
    Junqueira DR; Viana TG; Peixoto ER; Barros FC; Carvalho Md; Perini E
    Rev Assoc Med Bras (1992); 2011; 57(3):322-6. PubMed ID: 21691698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
    McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
    J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tainted heparin crisis tested FDA's investigative skills.
    Lavine G
    Am J Health Syst Pharm; 2009 Feb; 66(3):210-1. PubMed ID: 19179633
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cardiovascular system drugs. 10/12. The heparins].
    Nerich V; Limat S; Woronoff-Lemsi MC
    Soins; 2005 Mar; (693):51-3. PubMed ID: 15796485
    [No Abstract]   [Full Text] [Related]  

  • 16. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of galactosamine impurities in heparin samples by multivariate regression analysis of their (1)H NMR spectra.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    Anal Bioanal Chem; 2011 Jan; 399(2):635-49. PubMed ID: 20953772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins.
    Alban S; Lühn S; Schiemann S
    Anal Bioanal Chem; 2011 Jan; 399(2):681-90. PubMed ID: 20953779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Building a better heparin.
    Caughey GH
    Am J Respir Cell Mol Biol; 2003 Feb; 28(2):129-32. PubMed ID: 12540478
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of circular dichroism as a simple heparin-screening strategy.
    Stanley FE; Stalcup AM
    Anal Bioanal Chem; 2011 Jan; 399(2):701-6. PubMed ID: 20953771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.